Teroganova Nina, Girshkin Leah, Suter Catherine M, Green Melissa J
School of Psychiatry, University of New South Wales, Randwick, NSW, Australia.
Schizophrenia Research Institute, 405 Liverpool St, Darlinghurst, NSW, 2010, Australia.
BMC Genet. 2016 Jan 25;17:27. doi: 10.1186/s12863-016-0332-2.
Increasing evidence suggests the involvement of epigenetic processes in the development of schizophrenia and bipolar disorder, and recent reviews have focused on findings in post-mortem brain tissue. A systematic review was conducted to synthesise and evaluate the quality of available evidence for epigenetic modifications (specifically DNA methylation) in peripheral blood and saliva samples of schizophrenia and bipolar disorder patients in comparison to healthy controls.
Original research articles using humans were identified using electronic databases. There were 33 included studies for which data were extracted and graded in duplicate on 22 items of the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement, to assess methodological precision and quality of reporting.
There were 15 genome-wide and 18 exclusive candidate gene loci investigations for DNA methylation studies. A number of common genes were identified as differentially methylated in schizophrenia/bipolar disorder, which were related to reelin, brain-derived neurotrophic factor, dopamine (including the catechol-O-methyltransferase gene), serotonin and glutamate, despite inconsistent findings of hyper-, hypo-, or lack of methylation at these and other loci. The mean STROBE score of 59% suggested moderate quality of available evidence; however, wide methodological variability contributed to a lack of consistency in the way methylation levels were quantified, such that meta-analysis of the results was not possible.
Moderate quality of available evidence shows some convergence of differential methylation at some common genetic loci in schizophrenia and bipolar disorder, despite wide variation in methodology and reporting across studies. Improvement in the clarity of reporting clinical and other potential confounds would be useful in future studies of epigenetic processes in the context of exposure to environmental and other risk factors.
越来越多的证据表明表观遗传过程参与了精神分裂症和双相情感障碍的发展,最近的综述集中在死后脑组织的研究结果上。本研究进行了一项系统综述,以综合和评估与健康对照相比,精神分裂症和双相情感障碍患者外周血和唾液样本中表观遗传修饰(特别是DNA甲基化)的现有证据质量。
使用电子数据库识别使用人类的原始研究文章。共有33项纳入研究,对其数据进行提取,并根据流行病学观察性研究报告强化(STROBE)声明的22项内容进行双人评分,以评估方法的精确性和报告质量。
有15项全基因组和18项特定候选基因位点的DNA甲基化研究。在精神分裂症/双相情感障碍中,一些常见基因被确定为甲基化差异基因,这些基因与Reelin、脑源性神经营养因子、多巴胺(包括儿茶酚-O-甲基转移酶基因)、5-羟色胺和谷氨酸有关,尽管在这些位点和其他位点甲基化水平存在高甲基化、低甲基化或无甲基化的不一致结果。平均STROBE评分为59%,表明现有证据质量中等;然而,方法学的广泛差异导致甲基化水平量化方式缺乏一致性,因此无法对结果进行荟萃分析。
现有证据质量中等,表明在精神分裂症和双相情感障碍的一些常见基因位点上,甲基化差异存在一定程度的趋同,尽管各研究在方法学和报告方面存在广泛差异。在未来关于暴露于环境和其他风险因素背景下的表观遗传过程研究中,提高临床和其他潜在混杂因素报告的清晰度将很有帮助。